Barinthus appoints Douglas Swirsky as CFO, effective May 1, 2026

Barinthus Biotherapeutics plc.

Swirsky appointed Chief Financial Officer and principal accounting officer, effective May 1, 2026.
Previously served as CFO of MaxCyte (2023-2026) and AavantiBio; CEO of Rexahn Pharmaceuticals.
Compensation: $20,000 per month via master services agreement with Grand Strand BioAdvisors LLC.
Company will provide D&O insurance and indemnification on terms no less favorable than other officers.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.